Annals of translational medicine最新文献

{"title":"Clonal hematopoiesis of indeterminate potential (CHIP)-a pivotal contributor of aging and related disorders.","authors":"Ankita Dhenge, Rohan Kulkarni","doi":"10.21037/atm-2026-1-0030","DOIUrl":"10.21037/atm-2026-1-0030","url":null,"abstract":"<p><p>Aging is associated with organ and tissue function deterioration and consequent increased risk of disease occurrence and mortality. Recent scientific advancements have succeeded in increasing the human life span and attempts are being made to enhance the longevity further. This stretched longevity exposes the organism to increased cellular stress and accumulation of DNA damage. Mutations in leukemia-associated driver oncogenes like <i>DNMT3A</i>, <i>TET2</i>, <i>ASXL1</i>, <i>TP53</i>, <i>PPM1D</i>, <i>SF3B1</i>, <i>SRSF2</i>, and <i>IDH1/2</i>, provide selective growth advantage to the mutated clones over normal hematopoietic stem cells (HSCs). Altered bone marrow (BM) microenvironment and increased pro-inflammatory milieu further accelerates the clonal expansion and eventually reduces the hematopoietic heterogeneity. Significant increase in clonal hematopoiesis with more than two percent of peripheral blood cells arising from single hematopoietic clone is termed as clonal hematopoiesis of indeterminate potential (CHIP). CHIP is increasingly recognized as an age-associated risk factor linked to cardiovascular and neurological disorders. While epidemiological and experimental studies suggest mechanistic involvement of inflammation, current human evidence primarily supports risk association rather than definitive causality, which may vary across mutation types. Here, we have discussed the intrinsic and extrinsic changes occurring in the hematopoietic system and its role in enhancing the clonal expansion during aging. We have further discussed the role of CHIP in various diseases and diagnostic tools being currently used for CHIP diagnosis. Finally, we also discuss the current CHIP management strategies and global status of CHIP related research. Thus, the emerging CHIP-cantered research and new strategies to impede CHIP progression can play a critical role in the development of effective therapeutic strategies for managing age-related obnoxious disorders.</p>","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"14 3","pages":"34"},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13349727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148418105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limitations of large language model-generated multiple-choice questions in ophthalmology.","authors":"Vincent Xiao, Zachary Elkin, Christina Prescott, Jung G Kim, Kiran Malhotra","doi":"10.21037/atm-2026-0043","DOIUrl":"10.21037/atm-2026-0043","url":null,"abstract":"","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"14 3","pages":"41"},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13349726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148418266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of combining peripheral defocus spectacle lens wear with 0.01% atropine.","authors":"Sayantan Biswas, James S Wolffsohn","doi":"10.21037/atm-2026-0055","DOIUrl":"10.21037/atm-2026-0055","url":null,"abstract":"","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"14 3","pages":"39"},"PeriodicalIF":0.0,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13349730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148418286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Notoginsenoside R2 induces colonic microvascular injuries via regulating the Rap1GAP/PI3K/Akt signaling pathway.","authors":"","doi":"10.21037/atm-2024-34","DOIUrl":"10.21037/atm-2024-34","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.21037/atm-21-5898.].</p>","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"14 2","pages":"28"},"PeriodicalIF":0.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13184395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147980194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of pharmacological interventions for the treatment of sarcopenia.","authors":"Dan Yang, Lin Su, Liying Zhang, Yina Li, Tingxuan Huang, Xiaoli Huang","doi":"10.21037/atm-2025-1-184","DOIUrl":"10.21037/atm-2025-1-184","url":null,"abstract":"<p><p>Sarcopenia is a multifactorial age-related muscle disorder of which its underlying pathophysiological mechanisms remain incompletely understood. To date, treatment strategies of sarcopenia have been largely confined to lifestyle interventions, underscoring an urgent need for pharmacological options that directly target the biological drivers of muscle deterioration. Despite increasing interest in drug development for sarcopenia, no specific pharmacological agent has yet received regulatory approval. This review provides a comprehensive synthesis of recent advances in investigational pharmacotherapeutic options for sarcopenia, with a focus on their mechanistic pathways and evidence from clinical trials. Key emerging classes include selective androgen receptor modulators (SARMs), myostatin antibodies, monoclonal antibodies targeting activin type 2 receptors, ghrelin receptor agonists, and growth differentiation factor-15 (GDF-15) monoclonal antibodies. In parallel, existing medications including testosterone, antidiabetic agents, classical renin-angiotensin system (RAS) inhibitors and anti-inflammatory drugs, have shown ancillary benefits in older populations but lack robust, indication-specific data. A critical contradiction persists: while several candidates increase muscle mass, few consistently improve muscle strength or physical function, reflecting a disconnect between surrogate endpoints and clinically meaningful outcomes. Moreover, some trials have been conducted in heterogeneous populations without clearly defined sarcopenia, limiting interpretability. As mechanistic insights evolve and regulatory frameworks advance, the field requires not only more targeted therapies but also clearer definitions of efficacy and patient classification.</p>","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"14 2","pages":"19"},"PeriodicalIF":0.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13184398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147980155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitapivat for sickle cell disease: the time is ripe for a new therapy.","authors":"Aaron N Cheng, Hanny Al-Samkari","doi":"10.21037/atm-2026-1-0021","DOIUrl":"10.21037/atm-2026-1-0021","url":null,"abstract":"","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"14 2","pages":"20"},"PeriodicalIF":0.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13184406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147980199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"No significant impact of levothyroxine treatment of maternal subclinical hypothyroidism on brain morphology in adolescence: insight from long-term follow up of Controlled Antenatal Thyroid Screening (CATS) study.","authors":"Sun Y Lee","doi":"10.21037/atm-2026-1-0025","DOIUrl":"10.21037/atm-2026-1-0025","url":null,"abstract":"","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"14 2","pages":"23"},"PeriodicalIF":0.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13184394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147980228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seeing is not enough: why introducer choice matters in hyperangulated videolaryngoscopy.","authors":"Manuel Ángel Gómez-Ríos, Samuel Ern Hung Tsan, Miguel Á Fernández-Vaquero, Alfredo Abad-Gurumeta","doi":"10.21037/atm-2026-1-0013","DOIUrl":"10.21037/atm-2026-1-0013","url":null,"abstract":"","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"14 2","pages":"24"},"PeriodicalIF":0.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13184391/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147980253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breaking through the azacitidine plateau?-venetoclax in high-risk myelodysplastic syndrome.","authors":"Yuju An, Theodoros Karantanos","doi":"10.21037/atm-2026-1-0019","DOIUrl":"10.21037/atm-2026-1-0019","url":null,"abstract":"","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"14 2","pages":"26"},"PeriodicalIF":0.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13184396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147980213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Over-the-scope clips versus standard endoscopic therapy as first-line treatment for bleeding peptic ulcer disease: a systematic review and meta-analysis.","authors":"Hazem Abosheaishaa, Mohammed Y Youssef, Mohamed H Eldesouki, Mohamad Elgozair, Mina Iskander, Hossam Elnaggar, Layth Alzubaidy, Sharif Abbas, Ahmed Elsayed Alzamzamy, Arnold Forlemu, Madhavi Reddy","doi":"10.21037/atm-2026-1-0011","DOIUrl":"10.21037/atm-2026-1-0011","url":null,"abstract":"<p><strong>Background: </strong>Peptic ulcer bleeding remains a significant cause of non-variceal upper gastrointestinal bleeding (NVUGIB). While over-the-scope clips (OTSC) are increasingly used as rescue therapy, their efficacy as first-line treatment remains unclear. The aim of this study is to evaluate the efficacy and safety of OTSC compared to standard endoscopic therapy (SET) as a first-line treatment in patients with bleeding peptic ulcer disease (PUD).</p><p><strong>Methods: </strong>A systematic literature search was conducted across MEDLINE, Embase, Scopus, and Web of Science databases up to March 13, 2026. Studies comparing OTSC and SET in bleeding PUD were included. Primary outcome was Clinical Success. Secondary outcomes included primary and technical success, need for surgery or re-therapy, mortality, hospital stay, and adverse events. Meta-analyses were performed using a random-effects model.</p><p><strong>Results: </strong>Six studies [3 randomized controlled trials (RCTs), 3 observational] comprising 454 patients were included. OTSC significantly improved clinical success [risk ratio (RR) =1.16, 95% confidence interval (CI): 1.06-1.27, P=0.002]. OTSC also significantly reduced overall bleeding (RR =0.46, 95% CI: 0.25-0.82, P=0.009). No statistically significant differences were observed in primary success, technical success, 7- or 30-day rebleeding, need for re-therapy, surgical intervention, in-hospital mortality, total mortality, adverse events, or hospital stay.</p><p><strong>Conclusions: </strong>OTSC is associated with significantly higher clinical success and lower overall bleeding rates compared to SET in bleeding PUD. Secondary outcomes, including rebleeding, re-intervention, and mortality, trended in favour of OTSC but did not reach statistical significance, likely reflecting limited power. These findings support OTSC as a promising first-line option. Further large-scale RCTs are warranted to confirm these results and guide clinical implementation.</p>","PeriodicalId":8216,"journal":{"name":"Annals of translational medicine","volume":"14 2","pages":"14"},"PeriodicalIF":0.0,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13184400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147980158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}